Donal O’Shea

Professor Donal O'Shea, Clinical Lead for Obesity with the HSE, discusses new guidelines advocating for weight-loss medications as the first line of treatment for obesity. He highlights their effectiveness in preventing health issues like high blood pressure and diabetes. Donal emphasizes the importance of combining these drugs with lifestyle changes for optimal results. He also addresses common side effects and the economic benefits of public funding for long-term health savings. Insights on evolving treatment policies and the need for ongoing vigilance round out the conversation.

Professor Donal O’Shea, HSE Lead for Obesity and an endocrinologist, dives into the pressing issue of obesity, particularly among Irish women aged 44 to 59. He discusses hormonal changes, the effectiveness of medications like Ozempic, and offers insights on how social media can combat diet myths. O’Shea highlights the complexities of weight management in midlife, including the impact of menopause and sleep quality. He also addresses societal pressures and the importance of medical oversight when using weight loss medications, wrapping up with optimistic trends in public health initiatives.

Professor Donal O'Shea, an endocrinologist and HSE National Clinical Lead for Obesity, dives into the societal implications of GLP-1 weight-loss drugs. He discusses the increasing stigma around obesity fueled by the casual use of these medications by those without clinical need. Donal reveals the dangers of online prescribing and unregulated drugs being promoted on social media. He also addresses potential long-term health risks and the cultural pressure for unrealistic body ideals. Cautious optimism is advised as we explore the future of these treatments.